• 11847 - Draelos
    Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream
    Zoe D Draelos, MD; Emil A Tanghetti, MD
    Poster Abstract

  • 11846 - Draelos
    Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety
    Zoe D Draelos, MD; Emil A Tanghetti, MD; Linda Stein Gold, MD; Hilary Baldwin, MD; Leon H Kircik, MD; Eric Guenin, PharmD, PhD, MPH
    Poster Abstract

  • 11845 - Draelos
    Comparison of Cutaneous Irritation With Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005% Cream
    Zoe D Draelos, MD; Patricia Farris, MD; Hilary Baldwin, MD; Emil A Tanghetti, MD
    Poster Abstract

  • 11904 - Eichenfield
    Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children: The Pivotal Phase 3 ADORING Clinical Trial Program
    Lawrence F. Eichenfield, Jonathan I. Silverberg, Robert Bissonnette, Anna M. Tallman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, John E. Jett
    Poster Abstract

  • 11841 - Ezzedine
    Treatment Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
    Khaled Ezzedine, MD, PhD, John E. Harris, MD, PhD, Kristen Bibeau, PhD, MSPH, Pearl Grimes, MD, Nanja van Geel, MD, PhD, Davinder Parsad, MD, Mukta Tulpule, MBBS, Jackie Gardner, BA, Yan Valle, MSc, MBA, Gaone Tlhong Matewa, BBA, Jessy Gao, MA, Haobo Ren, PhD, Iltefat H. Hamzavi, MD
    Poster Abstract

  • 11839 - Farberg
    The 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (SCC) provides clinically actionable risk-stratification prognostic information for clinicians
    Aaron Farberg, Jennifer Siegel, Briana Rackley, Alison Fitzgerald, Anesh Prasai, Robert Cook
    Poster Abstract

  • 11834 - Ferris
    Efficacy and tolerability of roflumilast cream 0.3% in patients with chronic plaque psoriasis involvement on the face, intertriginous, or genital areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)
    Laura K. Ferris, April Armstrong, James Del Rosso, Zoe D. Draelos, Melinda Gooderham, Mark Lebwohl, Kim A. Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C. Higham, Patrick Burnett, David R. Berk
    Poster Abstract

  • 11859 - Gooderham
    PASI Regional Component Speed of Response and Cumulative Response in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab versus Guselkumab in the IXORA-R Trial
    Melinda Gooderham, Ronald Vender, Jeffrey Crowley, Chih-Ho Hong, Meghan Feely,, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green
    Poster Abstract

  • 11902 - Gordon
    Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
    Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Natalie Nunez Gomez, Diamant Thaci
    Abstract

  • 11856 - Gordon
    Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
    Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Natalie Nunez Gomez, Diamant Thaçi
    Poster Abstract

  • 11829 - Guan
    A Case of Unrelenting ‘Intertrigo’
    Linna Guan MD, Nayha Shetty MD, Tessa LeWitt MS4, Ben J. Friedman MD
    Poster Abstract

  • 11838 - Hebert
    PHASE 3 POOLED ANALYSIS OF SAFETY AND EFFICACY OF TRIFAROTENE 0.005% CREAM WITHIN ADOLESCENT POPULATION
    Adelaide Hebert, MD, Stephanie Lee, MD, Daniel Krowchuk, MD, Krysten Lisella Arekapudi, DNP, Pearl Kwong, MD
    Abstract

  • 11858 - King
    Integrated Safety Analysis of Baricitinib in Adults with Severe Alopecia Areata from Two Randomized Clinical Trials
    Brett King, Arash Mostaghimi, Yutaka Shimomura, Abraham Zlotogorski, Katrin Holzwarth, Maher Issa, Yves Dutronc, Sarah Stanley, Wen-Shuo Wu, Rodney Sinclair
    Poster Abstract

  • 11905 - Kircik
    Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials
    Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal R. Desai, Brad P. Glick, Howard Sofen, David S. Rubenstein, Anna M. Tallman, Janine Fournier, Philip M. Brown
    Poster Abstract

  • 11831 - Kircik
    Efficacy and safety by race and ethnicity in a randomized, double-blind, vehicle-controlled phase 2a study evaluating once-daily roflumilast foam 0.3% in patients with seborrheic dermatitis
    Leon H. Kircik, Andrew F. Alexis, Javier Alonso-Llamazares, Michael Bukhalo, Zoe D. Draelos, Laura K. Ferris, Edward Lain, Charles W. Lynde, Angela Y. Moore, Linda Stein Gold, Paul S. Yamauchi, Matthew Zirwas, Saori Kato, Robert C. Higham, David Krupa, Patrick Burnett, David R. Berk
    Poster Abstract

  • 11914 - Korman
    Deucravacitinib in Plaque Psoriasis: 2-Year Laboratory Results From the Phase 3 POETYK PSO Program
    Neil J Korman, Thierry Passeron, Kenneth B Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Diamant Thaçi
    Abstract

  • 11820 - Korman
    Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
    Neil J Korman, Thierry Passeron, Kenneth B Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Diamant Thaçi
    Poster Abstract

  • 11925 - Kurley
    Incorporating the 31-gene expression profile test stratifies survival outcomes and leads to improved survival compared to clinicopathologic factors alone: A Surveillance, Epidemiology, and End Results (SEER) Program collaboration
    Sarah J. Kurley PhD, Christine N. Bailey, MPH, Brian Martin PhD, Matthew S. Goldberg, MD, Valentina Petkov, MD, MPH, Kyle Covington, PhD
    Poster Abstract

  • 11863 - Kwon
    Long-Term Efficacy of Baricitinib in Patients with Severe Alopecia Areata: Week-52 Results from BRAVE-AA1 and BRAVE-AA2.
    Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair, Neil Korman, Yves Dutronc, Chen-Yen Lin, Guanglei Yu, Chiara Chiasserini, Jill McCollam, Brett King6
    Poster Abstract

  • 11912 - Lain
    Results From a National Psoriasis Foundation Survey of Patient Experiences With Topical Therapy and Associated Skin Atrophy
    Edward Lain, Andrea Murina, Leon Kircik, Matthew Brunner, Abby Jacobson
    Poster Abstract